“I feel that in the coming days it is the Serum Institute vaccine that will be the main vaccine, Bharat Biotech only a backup for emergency use in case of reinfection,” Dr Randeep Guleria told NDTV.
Dr Randeep Guleria, the chief of Delhi’s All-India Institute of Medical Sciences today said that Bharat Biotech’s coronavirus vaccine, which is still undergoing clinical trial, is likely to be the “back-up” vaccine in the coming days, as two vaccines got emergency approval from the country’s drug regulator.
“I feel that in the coming days it is the Serum Institute vaccine that will be the main vaccine, Bharat Biotech only a backup for emergency use in case of reinfection,” Dr Randeep Guleria told NDTV in an exclusive interview.
“By that their time they will get their dosage ready and by the time they will get the data which will be able to show that the phase 3 data is robust and they have enough events to show that it is efficacious and it is safe, we will be able to have that vaccine available. But the first few weeks, it will be the serum institute vaccine which will be rolled out. It has 50 million doses available,” Dr Guleria told NDTV.
The expert committee appointed by the government has reviewed all data on its “safety and immunogenicity” and gave permission for “restricted use in emergency situation in public interest”, the health ministry said today.
However, the Congress party today asked that the Indian government must explain why mandatory protocols and verification of data from stage-3 trials have been dispensed with while granting permission for the emergency use of the two COVID-19 vaccines. The opposition party said the issue is pertinent since no other country has apparently dispensed with these key processes.
Shashi Tharoor of the Congress tweeted: “Covaxin has not yet had Phase 3 trials. Approval was premature and could be dangerous. @drharshvardhan should please clarify. Its use should be avoided till full trials are over. India can start with the AstraZeneca vaccine in the meantime.”
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
